SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P.

Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.

A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.

Argus Jan 6 session

-3.21% close to close Open Argus

Details

News Market Reaction – SABS

On Jan 6, the day this news came out, SABS closed 3.21% below the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Market Context

This announcement highlights SAB BIO’s participation at the high-profile 44th Annual J.P. Morgan Hea...

Analysis

This announcement highlights SAB BIO’s participation at the high-profile 44th Annual J.P. Morgan Healthcare Conference, where management plans to present on January 15 at 7:30 a.m. PT. It follows recent milestones for SAB-142, including Phase 1 safety data with no serum sickness or anti-drug antibodies and initiation of the Phase 2b SAFEGUARD trial. Investors monitoring this name often track conference appearances alongside future clinical readouts expected in 2H 2027 and previously reported cash runway through 2028.

Key Figures

Conference edition: 44th Annual J.P. Morgan Healthcare Conference Presentation date: January 15, 2026 Presentation time PT: 7:30 a.m. PT +2 more

Conference edition

44th Annual J.P. Morgan Healthcare Conference

Event where SAB BIO will present

Presentation date

January 15, 2026

Scheduled conference presentation in San Francisco

Presentation time PT

7:30 a.m. PT

Start time of CEO presentation

Presentation time ET

10:30 a.m. ET

Start time of CEO presentation

Webcast replay window

30 days

Archived presentation available on company website

Historical Context

5 past events · Latest: Dec 18

5 events

1. Dec 18

   Clinical trial update

   24h Move

   -0.3%

   First patient dosed in Phase 2b SAFEGUARD trial for Stage 3 T1D.

2. Dec 17

   Clinical results

   24h Move

   -0.8%

   Phase 1 SAB-142 data showed favorable safety with no serum sickness or ADAs.

3. Dec 08

   Conference data

   24h Move

   -10.8%

   Presentation of SAB-142 clinical data at ATTD-Asia diabetes conference.

4. Nov 13

   Earnings and update

   24h Move

   -9.1%

   Q3 financials with strong cash position and progress on Phase 2b trial.

5. Nov 04

   Conference presentation

   24h Move

   +0.0%

   ISPAD conference presentations highlighting SAB-142 safety and mechanism data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunoglobulin, autoimmune diseases

2 terms

immunoglobulin medical

"developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes"

Immunoglobulins are proteins commonly known as antibodies that the body makes to recognize and neutralize viruses, bacteria and other foreign substances; they act like targeted security guards that bind to specific invaders. For investors, immunoglobulins matter because they are the basis for many diagnostic tests, therapeutic drugs and blood‑derived products, so changes in demand, manufacturing capacity, clinical trial results or regulatory approvals can directly affect company revenues and risk profiles.

autoimmune diseases medical

"for type 1 diabetes (T1D) and other autoimmune diseases, today announced"

Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44^th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA.

A live webcast of the presentation will be available in the “Investors” section of the SAB BIO website at www.sab.bio. An archived replay will be available on the Company’s website for approximately 30 days following the presentation.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.

CONTACTS

Investor Relations:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will SAB Biotherapeutics (SABS) present at the J.P. Morgan Healthcare Conference?

SAB Biotherapeutics will present on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET.

Who is presenting for SAB Biotherapeutics (SABS) at the January 2026 JPM conference?

The presentation will be delivered by CEO Samuel J. Reich.

How can investors watch the SAB Biotherapeutics (SABS) JPM presentation live?

A live webcast will be available in the Investors section of www.sab.bio.

Will SAB Biotherapeutics (SABS) provide a replay of the JPM presentation?

Yes. An archived replay will be available on the company website for approximately 30 days after the presentation.

What topics will SAB Biotherapeutics (SABS) likely cover in the JPM presentation?

The company is clinical-stage and develops hATG for type 1 diabetes and other autoimmune diseases, which are expected topics.

Where on the SAB Biotherapeutics (SABS) site is the JPM webcast posted?

The webcast will be posted in the Investors section of www.sab.bio.